Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Adalimumab and Infliximab in Ankylosing Spondylitis at Alzahra Hospital
IRCT20200412047047N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of adalimumab and infliximab in ankylosing spondylitis (AS) (2 arms), sponsored by Isfahan University of Medical Sciences. Started May 2020; status: completed.
02
Drugs
adalimumabinfliximab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on IRCT20200412047047N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200412047047N1.